BPMC – blueprint medicines corporation (US:NASDAQ)
Stock Stats
News
Blueprint Medicines Co. (NASDAQ: BPMC) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $125.00 price target on the stock.
Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $135.00 price target on the stock.
Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $135.00 price target on the stock.
Blueprint Medicines Co. (NASDAQ: BPMC) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $135.00 price target on the stock.
Recludix Pharma to Present Data Demonstrating its Oral STAT3 Inhibitor has Differentiated Efficacy and Safety as Compared to JAK/TYK2 Inhibition in In Vivo Models of Inflammatory Arthritis [Yahoo! Finance]
Form 4 Blueprint Medicines Corp For: Nov 20 Filed by: COATS LONNEL
Form 144 Blueprint Medicines Corp Filed by: COATS LONNEL
Form 144 Blueprint Medicines Corp Filed by: COATS LONNEL
Form SC 13G/A Blueprint Medicines Corp Filed by: PRICE T ROWE ASSOCIATES INC /MD/
Form 4 Blueprint Medicines Corp For: Nov 07 Filed by: Albers Jeffrey W.
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.